{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:12:38Z","timestamp":1793041958171,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:00:00Z","timestamp":1713916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370201"],"award-info":[{"award-number":["82370201"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070227"],"award-info":[{"award-number":["82070227"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82230006"],"award-info":[{"award-number":["82230006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Pujiang Program","award":["22PJ1409800"],"award-info":[{"award-number":["22PJ1409800"]}]},{"name":"Double First-Class Project","award":["WF510162602"],"award-info":[{"award-number":["WF510162602"]}]},{"name":"Shanghai Collaborative Innovation Program on Regenerative Medicine and Stem Cell Research","award":["2019CXJQ01"],"award-info":[{"award-number":["2019CXJQ01"]}]},{"DOI":"10.13039\/501100013313","name":"Overseas Expertise Introduction Project for Discipline Innovation","doi-asserted-by":"publisher","award":["B17029"],"award-info":[{"award-number":["B17029"]}],"id":[{"id":"10.13039\/501100013313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The autologous anti\u2013B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy LCAR-B38M has been approved for the treatment of relapsed and refractory multiple myeloma in many countries across the world under the name ciltacabtagene autoleucel. LEGEND-2 was the first-in-human trial of LCAR-B38M and yielded deep and durable therapeutic responses. Here, we reported the outcomes in LEGEND-2 after a minimal 5-year follow-up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Participants received an average dose of 0.5\u2009\u00d7\u200910<jats:sup>6<\/jats:sup> cells\/kg LCAR-B38M in split or single unfractionated infusions after cyclophosphamide-based lymphodepletion therapy. Investigator-assessed response, survival, safety and pharmacokinetics were evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Seventy-four participants enrolled and had a median follow-up of 65.4 months. The 5-year progression-free survival (PFS) and overall survival (OS) rates were 21.0% and 49.1%, with progressive flattening of the survival curves over time. Patients with complete response (CR) had longer PFS and OS, with 5-year rates of 28.4% and 65.7%, respectively. Twelve patients (16.2%) remained relapse-free irrespective of baseline high-risk cytogenetic abnormality and all had normal humoral immunity reconstituted. An ongoing CR closely correlated with several prognostic baseline indices including favorable performance status, immunoglobulin G subtype, and absence of extramedullary disease, as well as a combination cyclophosphamide and fludarabine preconditioning strategy. Sixty-two (83.8%) suffered progressive disease (PD) and\/or death; however, 61.1% of PD patients could well respond to subsequent therapies, among which, the proteasome inhibitor-based regimens benefited the most. Concerning the safety, hematologic and hepatic function recovery were not significantly different between non-PD and PD\/Death groups. A low rate of second primary malignancy (5.4%) and no severe virus infection were observed. The patients who tested positive for COVID-19 merely presented self-limiting symptoms. In addition, a sustainable CAR T population of one case with persistent remission was delineated, which was enriched with indolently proliferative and lowly cytotoxic CD4\/CD8 double-negative functional T lymphocytes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These data, representing the longest follow-up of BCMA-redirected CAR T-cell therapy to date, demonstrate long-term remission and survival with LCAR-B38M for advanced myeloma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>LEGEND-2 was registered under the trial numbers NCT03090659, ChiCTRONH-17012285.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13045-024-01530-z","type":"journal-article","created":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T11:02:14Z","timestamp":1713956534000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial"],"prefix":"10.1186","volume":"17","author":[{"given":"Jie","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bai-Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-He","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang-Shuang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Juan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Hong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Li","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Qing","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai-Juan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,24]]},"reference":[{"issue":"10297","key":"1530_CR1","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398(10297):314\u201324.","journal-title":"Lancet"},{"issue":"6","key":"1530_CR2","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.22.00690","volume":"41","author":"JQ Mi","year":"2023","unstructured":"Mi JQ, Zhao W, Jing H, Fu W, Hu J, Chen L, et al. Phase II, open-label study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese patients with Relapsed\/Refractory multiple myeloma (CARTIFAN-1). J Clin Oncol. 2023;41(6):1275\u201384.","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"1530_CR3","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1182\/blood-2023-178882","volume":"142","author":"J Hillengass","year":"2023","unstructured":"Hillengass J, Cohen AD, Agha ME, Delforge M, Kerre T, Roeloffzen W, et al. The phase 2 CARTITUDE-2 trial: updated efficacy and safety of Ciltacabtagene Autoleucel in patients with multiple myeloma and 1\u20133 prior lines of Therapy (Cohort A) and with early relapse after First Line treatment (cohort B). Blood. 2023;142(Supplement 1):1021.","journal-title":"Blood"},{"issue":"4","key":"1530_CR4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos MV, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory multiple myeloma. N Engl J Med. 2023;389(4):335\u201347.","journal-title":"N Engl J Med"},{"issue":"1","key":"1530_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","volume":"11","author":"WH Zhao","year":"2018","unstructured":"Zhao WH, Liu J, Wang BY, Chen YX, Cao XM, Yang Y, et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018;11(1):141.","journal-title":"J Hematol Oncol"},{"issue":"19","key":"1530_CR6","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1073\/pnas.1819745116","volume":"116","author":"J Xu","year":"2019","unstructured":"Xu J, Chen LJ, Yang SS, Sun Y, Wu W, Liu YF, et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma. Proc Natl Acad Sci U S A. 2019;116(19):9543\u201351.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1530_CR7","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","volume":"15","author":"WH Zhao","year":"2022","unstructured":"Zhao WH, Wang BY, Chen LJ, Fu WJ, Xu J, Liu J, et al. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). J Hematol Oncol. 2022;15(1):86.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"1530_CR8","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u2013e46.","journal-title":"Lancet Oncol"},{"issue":"21","key":"1530_CR9","doi-asserted-by":"publisher","first-page":"4615","DOI":"10.1016\/j.cell.2023.08.033","volume":"186","author":"S Yu","year":"2023","unstructured":"Yu S, Lin Y, Li Y, Chen S, Zhou L, Song H, et al. Systemic immune profiling of Omicron-infected subjects inoculated with different doses of inactivated virus vaccine. Cell. 2023;186(21):4615\u201331e16.","journal-title":"Cell"},{"key":"1530_CR10","doi-asserted-by":"crossref","unstructured":"Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013;88(4):360\u2009\u2013\u200976.","DOI":"10.1016\/j.mayocp.2013.01.019"},{"issue":"5","key":"1530_CR11","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","volume":"36","author":"MV Mateos","year":"2022","unstructured":"Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia. 2022;36(5):1371\u20136.","journal-title":"Leukemia"},{"issue":"8","key":"1530_CR12","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa1903455","volume":"381","author":"A Chari","year":"2019","unstructured":"Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381(8):727\u201338.","journal-title":"N Engl J Med"},{"issue":"6","key":"1530_CR13","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495\u2013505.","journal-title":"N Engl J Med"},{"issue":"10","key":"1530_CR14","doi-asserted-by":"publisher","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","volume":"10","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Hungria VTM, Radinoff A, Delimpasi S, Mikala G, Masszi T, et al. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023;10(10):e801\u2013e12.","journal-title":"Lancet Haematol"},{"issue":"6","key":"1530_CR15","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory multiple myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2023;41(6):1265\u201374.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1530_CR16","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.clml.2021.10.013","volume":"22","author":"LJ Costa","year":"2022","unstructured":"Costa LJ, Lin Y, Cornell RF, Martin T, Chhabra S, Usmani SZ, et al. Comparison of Cilta-cel, an Anti-BCMA CAR-T cell therapy, Versus Conventional treatment in patients with Relapsed\/Refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2022;22(5):326\u201335.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"1530_CR17","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1080\/03007995.2021.1953456","volume":"37","author":"T Martin","year":"2021","unstructured":"Martin T, Usmani SZ, Schecter JM, Vogel M, Jackson CC, Deraedt W, et al. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Curr Med Res Opin. 2021;37(10):1779\u201388.","journal-title":"Curr Med Res Opin"},{"issue":"Supplement 1","key":"1530_CR18","doi-asserted-by":"publisher","first-page":"6901","DOI":"10.1182\/blood-2023-182175","volume":"142","author":"W Alsdorf","year":"2023","unstructured":"Alsdorf W, Diels J, Ghilotti F, Mendes J, Hernando T, Cost P, et al. Efficacy of Carvykti in CARTITUDE-4 Versus other Conventional Treatment regimens for Lenalidomide-Refractory multiple myeloma patients using inverse probability of treatment weighting. Blood. 2023;142(Supplement 1):6901.","journal-title":"Blood"},{"issue":"12","key":"1530_CR19","doi-asserted-by":"publisher","first-page":"e897","DOI":"10.1016\/S2352-3026(22)00284-8","volume":"9","author":"T Martin","year":"2022","unstructured":"Martin T, Lin Y, Agha M, Cohen AD, Htut M, Stewart AK, et al. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study. Lancet Haematol. 2022;9(12):e897\u2013e905.","journal-title":"Lancet Haematol"},{"issue":"6","key":"1530_CR20","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20(6):359\u201371.","journal-title":"Nat Rev Clin Oncol"},{"issue":"32","key":"1530_CR21","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1200\/JCO.20.01467","volume":"38","author":"KM Cappell","year":"2020","unstructured":"Cappell KM, Sherry RM, Yang JC, Goff SL, Vanasse DA, McIntyre L, et al. Long-term Follow-Up of Anti-CD19 chimeric Antigen receptor T-Cell therapy. J Clin Oncol. 2020;38(32):3805\u201315.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1530_CR22","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1200\/JCO.21.02370","volume":"41","author":"M Wang","year":"2023","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. Three-year Follow-Up of KTE-X19 in patients with Relapsed\/Refractory Mantle Cell Lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2023;41(3):555\u201367.","journal-title":"J Clin Oncol"},{"issue":"21","key":"1530_CR23","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1182\/blood.2020008936","volume":"137","author":"D Wang","year":"2021","unstructured":"Wang D, Wang J, Hu G, Wang W, Xiao Y, Cai H, et al. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma. Blood. 2021;137(21):2890\u2013901.","journal-title":"Blood"},{"issue":"355","key":"1530_CR24","doi-asserted-by":"publisher","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","volume":"8","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, et al. Immunotherapy of non-hodgkin\u2019s lymphoma with a defined ratio of CD8\u2009+\u2009and CD4\u2009+\u2009CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8(355):355ra116.","journal-title":"Sci Transl Med"},{"issue":"7897","key":"1530_CR25","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, et al. Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells. Nature. 2022;602(7897):503\u20139.","journal-title":"Nature"},{"issue":"7","key":"1530_CR26","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1038\/s41591-023-02415-3","volume":"29","author":"ND Anderson","year":"2023","unstructured":"Anderson ND, Birch J, Accogli T, Criado I, Khabirova E, Parks C, et al. Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia. Nat Med. 2023;29(7):1700\u20139.","journal-title":"Nat Med"},{"issue":"4","key":"1530_CR27","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/imm.13441","volume":"165","author":"T Velikkakam","year":"2022","unstructured":"Velikkakam T, Gollob KJ, Dutra WO. Double-negative T cells: setting the stage for disease control or progression. Immunology. 2022;165(4):371\u201385.","journal-title":"Immunology"},{"key":"1530_CR28","doi-asserted-by":"publisher","first-page":"816005","DOI":"10.3389\/fimmu.2022.816005","volume":"13","author":"Z Wu","year":"2022","unstructured":"Wu Z, Zheng Y, Sheng J, Han Y, Yang Y, Pan H, et al. CD3(+)CD4(-)CD8(-) (Double-Negative) T cells in inflammation, Immune disorders and Cancer. Front Immunol. 2022;13:816005.","journal-title":"Front Immunol"},{"issue":"2","key":"1530_CR29","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jaad.2006.01.020","volume":"55","author":"E Hodak","year":"2006","unstructured":"Hodak E, David M, Maron L, Aviram A, Kaganovsky E, Feinmesser M. CD4\/CD8 double-negative epidermotropic cutaneous T-cell lymphoma: an immunohistochemical variant of mycosis fungoides. J Am Acad Dermatol. 2006;55(2):276\u201384.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1530_CR30","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.2340\/00015555-2102","volume":"95","author":"T Miyauchi","year":"2015","unstructured":"Miyauchi T, Abe R, Morita Y, Adachi M, Shiba K, Hamade Y, et al. CD4\/CD8 double-negative T-cell lymphoma: a variant of primary cutaneous CD8\u2009+\u2009aggressive epidermotropic cytotoxic T-cell lymphoma? Acta Derm Venereol. 2015;95(8):1024\u20135.","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"1530_CR31","doi-asserted-by":"publisher","first-page":"E478","DOI":"10.1002\/ajh.26745","volume":"97","author":"D Chen","year":"2022","unstructured":"Chen D, Wang X, Chen Z, Jiang S, Jiang H, Fu W, et al. Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed\/refractory multiple myeloma. Am J Hematol. 2022;97(12):E478\u2013E81.","journal-title":"Am J Hematol"},{"issue":"11","key":"1530_CR32","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1200\/JCO.22.01365","volume":"41","author":"DK Hansen","year":"2023","unstructured":"Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, et al. Idecabtagene Vicleucel for Relapsed\/Refractory multiple myeloma: real-world experience from the Myeloma CAR T Consortium. J Clin Oncol. 2023;41(11):2087\u201397.","journal-title":"J Clin Oncol"},{"issue":"13","key":"1530_CR33","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody S, Devlin SM, Landa J, Nath K, Diamonte C, Carstens EJ, et al. GPRC5D-Targeted CAR T cells for Myeloma. N Engl J Med. 2022;387(13):1196\u2013206.","journal-title":"N Engl J Med"},{"issue":"1","key":"1530_CR34","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1186\/s12967-023-04655-w","volume":"21","author":"D Wang","year":"2023","unstructured":"Wang D, Fu H, Que Y, Ruan H, Xu M, Long X, et al. A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed\/refractory extramedullary multiple myeloma. J Transl Med. 2023;21(1):812.","journal-title":"J Transl Med"},{"key":"1530_CR35","doi-asserted-by":"crossref","unstructured":"Ghilardi G, Fraietta JA, Gerson JN, Van Deerlin VM, Morrissette JJD, Caponetti GC et al. T-cell lymphoma and secondary primary malignancy risk after commercial CAR T-cell therapy. Nat Med. 2024.","DOI":"10.1038\/s41591-024-02826-w"},{"issue":"17","key":"1530_CR36","doi-asserted-by":"publisher","first-page":"5222","DOI":"10.1182\/bloodadvances.2022008093","volume":"6","author":"EM Hsieh","year":"2022","unstructured":"Hsieh EM, Myers RM, Yates B, Annesley C, John S, Taraseviciute A, et al. Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy. Blood Adv. 2022;6(17):5222\u20136.","journal-title":"Blood Adv"},{"issue":"1","key":"1530_CR37","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41467-023-44648-3","volume":"15","author":"S Yang","year":"2024","unstructured":"Yang S, Xu J, Dai Y, Jin S, Sun Y, Li J, et al. Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma. Nat Commun. 2024;15(1):360.","journal-title":"Nat Commun"},{"issue":"7709","key":"1530_CR38","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature. 2018;558(7709):307\u201312.","journal-title":"Nature"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01530-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-024-01530-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-024-01530-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T11:18:58Z","timestamp":1713957538000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-024-01530-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,24]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1530"],"URL":"https:\/\/doi.org\/10.1186\/s13045-024-01530-z","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,24]]},"assertion":[{"value":"3 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in accordance with the Declaration of Helsinki and was approved by the institutional independent ethics committee, including the Approval Committees of Second Affiliated Hospital of Xi\u2019an Jiao Tong University, Ruijin Hospital affiliated with Shanghai Jiao Tong University, First Affiliated Hospital of Nanjing Medical University, and Changzheng Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"23"}}